Atrix licenses Eligard to Japan's Sosei

Atrix Laboratories of the USA has licensed Japanese rights to itsEligard (leuprolide acetate) product to local biopharmaceutical company Sosei. In the USA, Eligard has been licensed to Sanofi-Synthelabo, which launched the product there last year (Marketletter June 3, 2002).

Under the terms of the agreement, valued at up to $30 million, Atrix receives an upfront license fee, R&D funding and payments for clinical, regulatory and sales milestones, as well as royalty payments based on sales of the Eligard products upon approval in Japan. In return, Sosei will be responsible for preclinical and clinical studies required for approval in Japan and submitting the regulatory dossier. Atrix will manufacture Eligard for Sosei.